Charles Choe, DO
General Practice · Flanders, NJNPI 1629081211
Payments from drug & device makers
Across 862 payments — averaging $13.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- AbbVie$963
- Lilly USA, LLC$868
- Pfizer$812
- plus $4K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 185 | $2,662 |
| AstraZeneca | 84 | $1,313 |
| Boehringer Ingelheim | 85 | $1,205 |
| AbbVie | 83 | $963 |
| Lilly USA, LLC | 49 | $868 |
| Pfizer | 108 | $812 |
| GSK | 35 | $503 |
| Merck | 32 | $452 |
| Currax Pharmaceuticals LLC | 28 | $341 |
| Bayer | 18 | $339 |
| Amarin Pharma, Inc. | 23 | $302 |
| Otsuka America Pharmaceutical, Inc. | 17 | $277 |
| Amgen(2 entities) | 18 | $268 |
| Axsome Therapeutics, Inc. | 13 | $235 |
| Exact Sciences | 9 | $211 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $128 |
| Medicem Inc. | 1 | $100 |
| Teva Pharmaceuticals USA, Inc. | 7 | $94 |
| Novartis | 7 | $91 |
| Johnson & Johnson | 6 | $86 |
| Eisai Inc. | 7 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $79 |
| Medtronic | 2 | $47 |
| Astellas Pharma US Inc | 2 | $45 |
| Abbott | 3 | $45 |
| Bausch Health US, LLC | 3 | $44 |
| Althera Pharmaceuticals LLC | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $28 |
| Shire North American Group Inc | 2 | $28 |
| Vivus LLC | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Lundbeck LLC | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Dermira, Inc. | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
How this compares
$11,859 in reported general payments places this provider in the 95th percentile of 2,978 general practice providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other general practice in Flanders
- Anthony MiccioFlanders$14K
- Suma GhantaFlanders$12K
- Karen PetersFlanders$9K
- Ryan LakeClark$914K
- Hua-Yu Steven LiaoLodi$816K
- Howard GlazerFort Lee$636K
- Frank LeeBradley Beach$417K
- Jeffrey ChustckieSomerset$165K
- John MinichettiEnglewood$142K
- Narenderan RajanHackettstown$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.